Research library
Individual studies, conference abstracts, patents and trial registrations. Each record identifies the study population or model, results and original source.
Find a study
Filter studies
Findings from selected studies
- Peptide persistence in mouse plasma
Radiolabeled HAEEPGP had approximately twice the plasma half-life of radiolabeled HAEE in mice. The comparison measured persistence in circulation.
1142 of 1142 records · Showing 30
2021 · Randomized trial · Full text available
Oral Epitalon for prolonged stress and Vilon during recovery from infection: two placebo comparisons ↗
Epitalon · Vilon
After 20 days, 87/270 Epimental recipients and 211/290 placebo recipients reported disturbed sleep. In the separate Regevil comparison, 110/276 and 200/244, respectively, reported fatigue.
Who or what was studied: Epimental: 560 adults aged 35–68 after prolonged occupational or emotional stress, including time-zone changes (270 active, 290 placebo). Regevil: 520 adults aged 43–76 recovering from acute respiratory, bacterial or viral illness (276 active, 244 placebo).
Read results, methods & source →2024 · Human comparative study · Full text available
Retinalamin in diabetic retinopathy: three-month imaging and electrical responses ↗
Retinalamin
At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.
Who or what was studied: 56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).
Read results, methods & source →2026 · Randomized trial · Russian-language source
Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration ↗
Retinalamin
At 720 days, mean light sensitivity in dry AMD eyes rose by 3.27 dB with Retinalamin and fell by 4.14 dB with placebo, a reported difference in change of 7.41 dB (p < 0.001). In treated wet AMD eyes, the within-group increase was statistically inconclusive (p = 0.302).
Who or what was studied: 21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).
Read results, methods & source →2018 · Uncontrolled human report · Full text available
Prostatilen AC: three-month sperm DNA fragmentation follow-up ↗
Prostatilen
Mean sperm DNA fragmentation fell from 17.8% to 7.5% at month one, then rose to 10.2% at month two and 16.2% at month three. The month-three change from baseline was statistically inconclusive.
Who or what was studied: 35 men aged 21–46 with chronic nonbacterial prostatitis, reproductive disturbances and a partner with a history of missed miscarriage.
Read results, methods & source →2022 · Randomized trial · Full text available
Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation ↗
Prostatilen
Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.
Who or what was studied: 90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.
Read results, methods & source →2023 · Randomized trial · Full text available
Prostatilen AC and infrared laser therapy in 97 men with idiopathic infertility ↗
Prostatilen
At two months, progressive sperm motility rose from 29.2% to 37.1% with the combination, versus 28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone. The authors reported a greater change with the combination (p < 0.01).
Who or what was studied: 97 men with idiopathic infertility, randomized to laser (34), Prostatilen AC (31), or both treatments (32).
Read results, methods & source →2013 · Uncontrolled human report · English abstract
Pancragen Forte: four weeks in 12 older adults with impaired glucose tolerance ↗
Pancragen
After four weeks of Pancragen Forte at 500 µg twice daily, the authors reported lower glucose during a tolerance test in half of the 12 treated adults. The abstract leaves the size of the change and the response threshold unspecified.
Who or what was studied: 12 older adults with impaired glucose tolerance received treatment. The screening sample included 150 people across three age groups, of whom 69 were 60 or older.
Read results, methods & source →2007 · Animal / experimental · English abstract
Pancragen in diabetic rats: blood glucose and mesenteric capillary outcomes ↗
Pancragen
The authors reported lower blood glucose during oral treatment and normalization of endothelial adhesion measures after intramuscular treatment. Capillary permeability was unchanged with intramuscular treatment.
Who or what was studied: Wistar rats with streptozotocin-induced diabetes. The abstract leaves arm sizes, doses and observation time unspecified.
Read results, methods & source →2015 · Uncontrolled human report · Full text available
Retinalamin in retinal dystrophy: a 46-patient long-term comparison ↗
Retinalamin
Visual acuity improved after the first course in 18/31 Retinalamin recipients and 4/15 comparison patients. After 23–25 years, 6/9 patients with pigmentary retinal dystrophy in the longer-treatment group had residual or object vision versus 0/11 comparison patients.
Who or what was studied: 46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.
Read results, methods & source →2021 · Human comparative study · Full text available
Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration ↗
Retinalamin · Cortexin · Ventfort
Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.
Who or what was studied: 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
Read results, methods & source →2008 · Animal / experimental · Full text available
Pancragen in irradiated older rats: pancreatic proliferation markers ↗
Pancragen · KED
Pancreatic PCNA-positive density was 8,176 per mm² with Pancragen and 6,524 per mm² with irradiation alone. T-38 was tested in a separate arm and had a density of 7,812 per mm².
Who or what was studied: 50 male Wistar rats, five groups of ten: young intact, aged intact, aged irradiated, aged irradiated plus T-38, and aged irradiated plus Pancragen.
Read results, methods & source →2013 · Human comparative study · Russian-language source
Suprefort with and without Cerluten and Endoluten in type 2 diabetes ↗
Suprefort · Cerluten · Endoluten
The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.
Who or what was studied: 918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
Read results, methods & source →2013 · Human comparative study · Russian-language source
Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis ↗
Ventfort · Cerluten · Svetinorm · Endoluten
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
Who or what was studied: 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
Read results, methods & source →2013 · Randomized trial · Russian-language source
Normophthal added to Retinalamin for early age-related macular degeneration ↗
Normophthal · Retinalamin
After 40 days, uncorrected visual acuity in the 45–59-year subgroup was 0.62 with adjunctive Normophthal and 0.60 with Retinalamin alone. The author reports no significant additional clinical effect in the oldest subgroup.
Who or what was studied: 120 patients with early age-related macular degeneration, 213 eyes: 67 in the combination group and 53 in the Retinalamin group.
Read results, methods & source →2019 · Human comparative study · Russian-language source
Zhenoluten and Endoluten in women with reduced reproductive function ↗
Zhenoluten · Endoluten
In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.
Who or what was studied: 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.
Read results, methods & source →2017 · Human comparative study · English abstract
Tireogen and Endoluten as adjuncts in autoimmune thyroiditis ↗
Tireogen · Endoluten
At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.
Who or what was studied: 218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.
Read results, methods & source →2007 · Animal / experimental · English abstract
Pancragen and pancreatic cell markers in streptozotocin-treated rats ↗
Pancragen
Insulin-positive pancreatic cell area was 6.43% with injected Pancragen, 5.53% with oral Pancragen and 2.42% with streptozotocin alone. Insulin staining intensity was similar across groups.
Who or what was studied: 28 male Wistar rats, four groups of seven: intact, streptozotocin only, streptozotocin with intramuscular Pancragen, and streptozotocin with oral Pancragen.
Read results, methods & source →2017 · Animal / experimental · Full text available
Slavinorm and cortical microcirculation in older hypertensive rats ↗
Vasolin / Slavinorm
Cortical microvessel density was about 1.7 times that of untreated hypertensive rats two months after one course. Perfusion rose but remained below that of normotensive rats.
Who or what was studied: 41 male rats: 12 treated hypertensive, 19 untreated hypertensive, 10 normotensive controls
Read results, methods & source →2017 · Animal / experimental · Full text available
Slavinorm and cortical microcirculation after one or two courses in hypertensive rats ↗
Vasolin / Slavinorm
After two courses, older rats had about 1.6 times the cortical microvessel density and about 15% higher perfusion than untreated hypertensive rats of the same age.
Who or what was studied: Four groups of hypertensive male rats (6, 14, 6 and 14), with a normotensive reference group
Read results, methods & source →2021 · Human comparative study · Full text available
Trekrezan in 130 adults with acute respiratory viral infections ↗
Trekrezan
In an open comparison of 130 adults, respiratory symptoms resolved an average of 2.2 days sooner in the Trekrezan group.
Who or what was studied: 130 adults with mild-to-moderate acute respiratory viral infection. Trekrezan: 100. Symptomatic-care comparison: 30. SARS-CoV-2-positive patients were excluded.
Read results, methods & source →2023 · Human comparative study · Full text available
Trekrezan in adults and adolescents with acute respiratory viral infections ↗
Trekrezan
Adolescent fever lasted 2.5 days less with Trekrezan. At days 3–5, fatigue persisted in 47.3% of treated adults and 70% of adult controls drawn from the earlier study.
Who or what was studied: 172 outpatients. Trekrezan plus symptomatic care: 75 adults and 47 adolescents. Symptomatic care: 30 adults and 20 adolescents. All 30 adult controls came from the 2021 Frolova study.
Read results, methods & source →2021 · Human comparative study · Full text available
Trekrezan in 80 outpatients with fatigue after COVID-19 ↗
Trekrezan
After eight days, 32 of 40 Trekrezan recipients and 8 of 40 controls had no fatigue on the study scale. The 2021 and 2022 reports describe the same 80 patients.
Who or what was studied: 80 adults within one month of outpatient COVID-19. Trekrezan: 40. Comparison with no Trekrezan: 40.
Read results, methods & source →2022 · Human comparative study · Full text available
Trekrezan in 103 inpatients with ongoing symptoms after COVID-19 ↗
Trekrezan
Mean MFI-20 fatigue scores fell from 44.5 to 31.9 with add-on Trekrezan and from 41.2 to 36.7 in the comparison group. Hospital stays averaged 11.4 vs 12.5 days.
Who or what was studied: 103 hospital inpatients with ongoing symptoms after moderate or severe COVID-19. Background care plus Trekrezan: 53. Background care without adaptogens: 50.
Read results, methods & source →2021 · Human comparative study · English abstract
Dilept versus risperidone in a 28-day psychiatric comparison ↗
Dilept
A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.
Who or what was studied: 25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.
Read results, methods & source →2017 · Human comparative study · Full text available
Dose-ranging cognitive report from the 25-patient Dilept pilot ↗
Dilept
The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.
Who or what was studied: 25 patients, mean age 33.4 ± 10.0 years, with ICD-10 F21.3. Dose groups: 5 at 60 mg/day, 5 at 120 mg/day and 15 at 200 mg/day. Seventy healthy volunteers provided reference test scores.
Read results, methods & source →2009 · Animal / experimental · English abstract
Dilept formulation and metabolite exposure in rats ↗
Dilept
Unformulated oral Dilept had less than 1% absolute bioavailability in rats. The tablet improved oral exposure, and two metabolites remained detectable in blood for more than four hours.
Who or what was studied: Rats. The abstract does not provide group sizes.
Read results, methods & source →2026 · Human comparative study · Russian-language source
Mexidol and cognitive testing in 90 older adults with chronic cerebral ischemia ↗
Mexidol
At three months, median MMSE was 27 vs 26 points. Schulte test time fell by 8 vs 2 seconds with add-on Mexidol and standard care alone, respectively.
Who or what was studied: 90 adults, mean age 81 ± 3, with chronic cerebral ischemia and cognitive impairment. Standard care plus Mexidol: 43. Standard care alone: 47.
Read results, methods & source →2026 · Human comparative study · Russian-language source
Mexidol with robotic rehabilitation in 47 children with spastic cerebral palsy ↗
Mexidol
The authors reported improvements of 37.6–58.7% across motor measures with Mexidol plus robotic rehabilitation, versus 24–39% with rehabilitation alone.
Who or what was studied: 47 children aged 6–8 years with spastic cerebral palsy. Mexidol plus robotic rehabilitation: 24. Robotic rehabilitation alone: 23.
Read results, methods & source →2004 · Human comparative study · Full text available
Gepon and Immunomax in 126 people with acute surgical wound infections ↗
Gepon & ezrin-derived peptides
In wounds healing by secondary intention, healing averaged 18.4 vs 20.5 days with the combination and comparison care, respectively.
Who or what was studied: 126 surgical patients with acute purulent soft-tissue infection. Combination group: 65. Standard-care comparison: 61.
Read results, methods & source →1994 · Randomized trial · English abstract
Thymopentin as add-on treatment for severe atopic dermatitis ↗
Thymopentin
The 39-person double-blind trial reported significantly greater improvement at week 12 with thymopentin as an adjunct to usual eczema care.
Who or what was studied: 39 patients at least two years old with severe eczema involving at least 20% of the skin surface. Arm-level sample sizes are unavailable in the abstract.
Read results, methods & source →Related collections
Compound and peptide patents ↗
Read claimed inventions, family links and identity checks.
Placebo-controlled studies ↗
Compare human results, masking and randomization.
Research topics ↗
Follow stroke, performance, peptide families and other questions.
Bibliography & PDFs ↗
Open original papers, dissertations and source collections.
FMBA & EMERCOM archive ↗
Find the original volumes, chamber studies and the PPK source trail.
Educational information, not medical advice. Seek qualified healthcare help for medical conditions. Source access describes the linked material; it does not imply that every method has been appraised.